Abstract:The transcription factor CCAAT/enhancer‐binding protein β (C/EBPβ) is highly expressed in various tissues during development, including liver, adipose tissue, blood cells, lung and the endocrine pancreas. Two isoforms of C/EBPβ namely liver‐enriched activator protein (LAP) and liver‐enriched inhibitor protein (LIP) translated from the same mRNA have been described. The LAP and LIP isoforms share the same C‐terminal DNA binding domain except LAP has an extra N‐terminal activation domain. Probably due to its higher affinity for its DNA cognate sequences, the LIP can counteract the effects of LAP isoforms even at substoichiometric levels. In vitro and in vivo experiments with cultured cells and knockout mice demonstrated that C/EBPβ play a critical role in the regulation of myofibroblast differentiation and bleomycin induced pulmonary fibrosis. However, the regulatory mechanism of C/EBPβ gene expression is unclear. Analysis of the C/EBPβ promoter sequence identified a conserved P53 response element (P53RE) in the C/EBPβ gene promoter. Gel shift mobility and chromatin immunoprecipitation assays confirmed that P53 binds to the P53RE. Promoter reporter assays and real time PCR analysis of samples from fibroblasts transiently transfected with P53 or dominant negative P53 expression plasmids indicated that P53 was a repressor of C/EBPβ gene transcription. Western blot analysis with protein extracts from similarly transfected fibroblasts or P53 deficient fibroblasts showed that P53 differentially regulated translation of the C/EBPβ LAP and LIP isoforms through the regulation of eIF4E and eIF4E‐BP1. Further studies with constructs containing the LAP 5′ untranslated region or the LIP 5′ untranslated region showed that the 5′ untranslated region is important in differential control of C/EBPβ LAP and LIP translation. Thus P53 could regulate C/EBPβ gene expression at both transcriptional and translational levels. Support or Funding Information This work was supported by grants HL052285 and HL112880 from the National Institute of Health.

The progress of research on the negative regulator of P53,PACT

Pact Is A Negative Regulator Of P53 And Essential For Cell Growth And Embryonic Development

Small Molecule Inhibitors of the P53-Mdm2

Transcriptional and translational regulation of CCAAT/Enhancer Binding Protein β expression by P53

Functional Diversity of P53 in Human and Wild Animals

The Biological Function and the Regulatory Roles of Wild-Type P53-Induced Phosphatase 1 in Immune System

Negative auto-regulators trap p53 in their web

CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status

Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity

[Advances on Mutant P53 Research].

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Rbb, A Novel Transcription Repressor, Represses the Transcription of Hdm2 Oncogene

p53 family in development.

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Regulation of P53 Stability As a Therapeutic Strategy for Cancer.

Negative Regulation Of Hdm2 To Attenuate P53 Degradation By Ribosomal Protein L26

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules

Abstract 5644: The impact of ATF3, JDP2, FOXR2, NAA10, FOXL2, DDX20, and p14ARF on the transactivation of p53

The Janus Face of P53-Targeting Ubiquitin Ligases

Advances in Study of Murine Double Minute 2/p53 Passway with Breast Cancer